1
项与 Personalized Neoantigen Peptide-Based Vaccine(Mayo Clinic) 相关的临床试验A Phase I/II Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA)
This phase I trial tests the safety and tolerability of an experimental personalized vaccine when given by itself and with pembrolizumab in treating patients with solid tumor cancers that have spread to other places in the body (advanced). The experimental vaccine is designed target certain proteins (neoantigens) on individuals' tumor cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving the personalized neoantigen peptide-based vaccine with pembrolizumab may be safe and effective in treating patients with advanced solid tumors.
100 项与 Personalized Neoantigen Peptide-Based Vaccine(Mayo Clinic) 相关的临床结果
100 项与 Personalized Neoantigen Peptide-Based Vaccine(Mayo Clinic) 相关的转化医学
100 项与 Personalized Neoantigen Peptide-Based Vaccine(Mayo Clinic) 相关的专利(医药)
100 项与 Personalized Neoantigen Peptide-Based Vaccine(Mayo Clinic) 相关的药物交易